JIR
KNSA icon

James Investment Research’s Kiniksa Pharmaceuticals KNSA Stock Holding History

James Investment Research’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$449K Hold
7,027
– – 0.05% 274
2026
Q1 		$338K Hold
7,027
– – 0.04% 287
2025
Q4 		$290K Hold
7,027
– – 0.03% 302
2025
Q3 		$273K Buy
+7,027
New +$228K 0.03% 301
2023
Q2 		– Sell
-4,118
Closed -$44K – 420
2023
Q1 		$44K Buy
+4,118
New +$54.3K 0.01% 372

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

James Investment Research's KNSA Position: Q2 2026 in Review

James Investment Research held its Kiniksa Pharmaceuticals (KNSA) position steady in Q2 2026 at 7,027 shares worth $449K. The position accounts for 0.05% of the portfolio, ranked #274.

James Investment Research first reported a position in KNSA in Q1 2023 and has held it in 5 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • James Investment Research held 7,027 shares of Kiniksa Pharmaceuticals worth $449K as of Q2 2026.
  • James Investment Research left its Kiniksa Pharmaceuticals share count unchanged in Q2 2026.
  • Kiniksa Pharmaceuticals made up 0.05% of James Investment Research's portfolio in Q2 2026, its #274 holding.
  • James Investment Research first reported a position in Kiniksa Pharmaceuticals in Q1 2023 and has held it in 5 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on James Investment Research's 13F filing for Q2 2026, filed 24 Jul 2026.